Vaccine billions

BioNTech, which received €325 million ($397 million) from the German government for the development of the vaccine, said it is committed to supplying low-income countries with its vaccine at cost. “We all know that no one will be safe until everyone is safe,” the company added.In a statement shared with CNN Business, it said that complex manufacturing processes and the length of time it takes to build new factories are among the major obstacles to increasing the global supply of vaccines. “Patents are not the limiting factor,” it said.BioNTech made a net profit of €1.1 billion ($1.3 billion) in the first three months of the year, largely thanks to its share of sales from the Covid-19 vaccine, compared with a loss of €53.4 million ($75.9 million) for the same period last year.

Pfizer and Moderna could score $32 billion in Covid-19 vaccine sales — in 2021 aloneModerna’s Covid-19 vaccine sales hit $1.7 billion in the first three months of this year and it had its first profitable […]